FIELD: chemistry.
SUBSTANCE: invention relates to a novel compound of formula I and a pharmaceutically acceptable salt thereof. In formula I Z is
X is CH or N, R1 is H, R2 is H or F, R3 is H, CH3 or F, R4 is H, CN, OCH3, 1-ethyl-1H-pyrazol-4-yl, 1-(2-methoxyethyl)-1H-pyrazol-4-yl or 1-(2-pyrrolidin-1-ylethyl)-1H-pyrazol-4-yl, R5 is H, CH3, F or OCH3, R6 is CN or 2-pyrimidinyl, R7 is Het2, Het2 is pyrazolyl or imidazolyl, each of which can be substituted with A, A is a straight or branched alkyl containing from 1 to 6 C atoms, where from 1 to 3 H atoms can be replaced by F and/or OH. Invention also relates to a process for the preparation of compounds of formula I by reacting a compound of formula II with a compound of formula III
where Z, R1, R2 and R3 are as defined in claim 1 and L is Cl, Br, I or a free or reactive functionally modified OH group.
EFFECT: compounds possess the properties of a tankyrase inhibitor (TANK) and/or poly (ADP-ribose) polymerase (PARP) and can be used for the treatment of diseases such as malignant neoplasm, multiple sclerosis, cardiovascular diseases, CNS lesions and various forms of inflammation.
4 cl, 2 tbl, 12 ex
Title | Year | Author | Number |
---|---|---|---|
QUINAZOLINONE DERIVATIVES AS PARP INHIBITORS | 2013 |
|
RU2650107C2 |
PIPERIDINE UREA DERIVATIVES | 2014 |
|
RU2666894C2 |
QUINOLINE-2 DERIVATIVES AS C-KIT KINASE INHIBITORS | 2016 |
|
RU2754858C2 |
4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
TLR7/8 ANTAGONISTS AND THEIR APPLICATION | 2017 |
|
RU2758686C2 |
SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS | 2011 |
|
RU2652638C2 |
PYRAZOLE DERIVATIVES APPLIED AS PROTEIN KINASE INHIBITORS | 2001 |
|
RU2340611C2 |
FURO[3,2-B]- AND THIENO[3,2-B]PYRIDINE DERIVATIVES AS TBK1 AND IKKε INHIBITORS | 2013 |
|
RU2622034C2 |
PHTHALAZINE DERIVATIVES | 2014 |
|
RU2663623C2 |
MACROCYCLIC PYRIDAZINONE DERIVATIVES | 2014 |
|
RU2660435C2 |
Authors
Dates
2018-10-11—Published
2014-07-10—Filed